Until recently, almost all studies of HER2 status focused on one type of malignancy, making it difficult to compare the rate of HER2 positivity across studies and tumor types.36-40 Furthermore, HER2 overexpression or amplification is most often evaluated by IHC or FISH, rather than NGS.41,42 However, in the current era of personalized cancer therapy, NGS is becoming more widely used. The gene discussed is ERBB2; the disease is neoplasm.